Nothing Special   »   [go: up one dir, main page]

MX2022010207A - Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o andamiaje no ig anti-adm para usarse en terapia o prevencion de choque. - Google Patents

Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o andamiaje no ig anti-adm para usarse en terapia o prevencion de choque.

Info

Publication number
MX2022010207A
MX2022010207A MX2022010207A MX2022010207A MX2022010207A MX 2022010207 A MX2022010207 A MX 2022010207A MX 2022010207 A MX2022010207 A MX 2022010207A MX 2022010207 A MX2022010207 A MX 2022010207A MX 2022010207 A MX2022010207 A MX 2022010207A
Authority
MX
Mexico
Prior art keywords
adm
antibody
scaffold
adrenomedullin
shock
Prior art date
Application number
MX2022010207A
Other languages
English (en)
Inventor
Andreas Bergmann
Original Assignee
Adrenomed Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adrenomed Ag filed Critical Adrenomed Ag
Publication of MX2022010207A publication Critical patent/MX2022010207A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001144—Hormones, e.g. calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente solicitud se refiere a un anticuerpo anti-adrenomedulina (ADM) o un fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para usarse en el tratamiento o prevención de choque en un paciente, en donde dicho paciente se caracteriza por tener un nivel de dipeptidil peptidasa 3 (DPP3) en una muestra de fluido corporal por debajo de un umbral y dicho anticuerpo anti-ADM o fragmento anti-ADM o andamiaje no Ig anti-ADM se une a la parte N-terminal (aminoácido 1-21) de ADM: YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 14).
MX2022010207A 2020-02-27 2021-03-01 Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o andamiaje no ig anti-adm para usarse en terapia o prevencion de choque. MX2022010207A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20159913 2020-02-27
PCT/EP2021/055059 WO2021170876A1 (en) 2020-02-27 2021-03-01 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock

Publications (1)

Publication Number Publication Date
MX2022010207A true MX2022010207A (es) 2022-11-16

Family

ID=69742840

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010207A MX2022010207A (es) 2020-02-27 2021-03-01 Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o andamiaje no ig anti-adm para usarse en terapia o prevencion de choque.

Country Status (11)

Country Link
US (1) US20230104578A1 (es)
EP (1) EP4110811A1 (es)
JP (1) JP2023515042A (es)
KR (1) KR20220145897A (es)
CN (1) CN115244080A (es)
AU (1) AU2021227277A1 (es)
BR (1) BR112022016528A2 (es)
CA (1) CA3168978A1 (es)
IL (1) IL295728A (es)
MX (1) MX2022010207A (es)
WO (1) WO2021170876A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315632A (en) * 2022-03-15 2024-11-01 Adrenomed Ag Stable aqueous formulation containing anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment
WO2024023369A1 (en) * 2022-07-29 2024-02-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
IL160289A0 (en) 2001-08-30 2004-07-25 Biorexis Pharmaceutical Corp Modified transferrin fusion proteins
DK2298278T3 (en) 2002-06-07 2016-02-01 Dyax Corp Prevention and reduction of blood loss and inflammatory response
WO2004097423A1 (en) 2003-04-25 2004-11-11 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2006027147A2 (en) 2004-09-09 2006-03-16 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2006032436A2 (en) 2004-09-21 2006-03-30 Nascacell Technologies Ag. Use of microproteins as tryptase inhibitors
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
ES2836948T3 (es) 2008-11-03 2021-06-28 Molecular Partners Ag Proteínas de unión que inhiben la interacción del receptor de VEGF-A
BR112012004314A2 (pt) 2009-08-27 2016-11-29 Covagen Ag compostos de ligação a il-17 e usos medicinais desses compostos
CA2782093A1 (en) 2009-12-14 2011-06-23 Scil Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
HUE043835T2 (hu) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh IL-4 receptor-alfát kötõ könny-lipokalin muteinek
LT3553084T (lt) 2011-11-16 2023-03-10 Adrenomed Ag Anti-adrenomedulino (adm) antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne-ig karkasas, skirtas organų funkcijos sutrikimo arba organų nepakankamumo profilaktikai arba sumažinimui paciento, sergančio lėtine arba ūmine liga arba esančio ūminės būklės, organizme
BR122019027917B1 (pt) 2011-11-16 2023-05-09 Adrenomed Ag Uso de um anticorpo anti-adrenomedulina (adm) enxertado em cdr humano ou humanizado ou fragmento de anticorpo anti-adm do mesmo
DK2780371T3 (en) 2011-11-16 2019-02-25 Adrenomed Ag ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE
DK2780370T3 (da) 2011-11-16 2019-10-28 Adrenomed Ag Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-ikke-ig skelet til anvendelse i terapi af en akut sygdom eller akut tilstand af en patient til at stabilisere kredsløbet
SG11201402362VA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
EP4417218A3 (en) 2016-04-21 2024-11-13 4TEEN4 Pharmaceuticals GmbH Methods for determining dpp3 and therapeutic methods
CN110167962B (zh) * 2016-12-16 2024-06-07 艾德里诺医药公司 用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
BR112020005450A2 (pt) * 2017-09-25 2020-09-29 Adrenomed Ag aglutinante antiadrenomedulina (adm) para uso em terapia ou prevenção dos sintomas de doença
AU2018350861A1 (en) * 2017-10-18 2020-04-09 Adrenomed Ag Therapy monitoring under treatment with an anti-adrenomedullin (ADM) binder
BR112022002856A2 (pt) * 2019-08-30 2022-08-09 4TEEN4 Pharmaceuticals GmbH Orientação de terapia e/ou monitoramento de terapia para o tratamento de choque

Also Published As

Publication number Publication date
KR20220145897A (ko) 2022-10-31
BR112022016528A2 (pt) 2022-11-16
IL295728A (en) 2022-10-01
CA3168978A1 (en) 2021-09-02
AU2021227277A1 (en) 2022-10-20
CN115244080A (zh) 2022-10-25
WO2021170876A1 (en) 2021-09-02
JP2023515042A (ja) 2023-04-12
EP4110811A1 (en) 2023-01-04
US20230104578A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
MX2022010207A (es) Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o andamiaje no ig anti-adm para usarse en terapia o prevencion de choque.
Ueno et al. Intrinsic prostacyclin contributes to exudation induced by bradykinin or carrageenin: a study on the paw edema induced in IP-receptor-deficient mice
ATE441418T1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
EA200801538A1 (ru) Лечение диабета 2 типа комбинацией ингибитора дипептидилпептидазы iv (dpiv) и метформина или тиазолидиндиона
NO20071093L (no) Nye anti-IGF-IR-antistoffer og anvendelse derav
PL1928499T3 (pl) Zastosowanie inhibitora DPP-IV do ograniczania epizodów hipoglikemii
ITMI20021527A1 (it) Anticorpi anti componente c5 del complemento e loro uso
HK1068798A1 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
EA200970335A1 (ru) Композиции и способы для диагностики и лечения рака
NZ623576A (en) Tfpi inhibitors and methods of use
RU2014150548A (ru) Терапевтическое средство от зуда
JP2004504032A5 (es)
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2024011278A (es) Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
MA34547B1 (fr) Traitement d'association pour traiter une infection par le vhc
WO2022170126A3 (en) Compounds specific to coronavirus s protein and uses thereof
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
EP2114431A4 (en) ARAZYME-CONTAINING COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER
ZA202305217B (en) Anti-tigit antibody, and pharmaceutical composition and use thereof
RU2019122135A (ru) Антитело против адреномедуллина (adm) или фрагмент анти-adm антитела, или анти-adm не-ig каркас для применения при вмешательстве и терапии гиперемии у пациента
MX2021003127A (es) Uso de un inhibidor de catepsina s contra la formacion de anticuerpos antifarmaco.
MX2023000763A (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
MX2021015501A (es) Anticuerpos y metodos de uso.